Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Sep 14;130(11):1375-1377.
doi: 10.1182/blood-2017-05-784678. Epub 2017 Jul 21.

Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma

Joseph M Connors  1 , Stephen M Ansell  2 , Michelle Fanale  3 , Steven I Park  4 , Anas Younes  5
Affiliations
Clinical Trial

Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma

Joseph M Connors et al. Blood. .

Abstract

Publisher's Note: There is an Inside Blood Commentary on this article in this issue.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: J.M.C.’s institution receives support for research from F Hoffmann-La Roche; Bristol-Myers Squibb; Takeda Pharmaceutical Company; and Seattle Genetics. S.I.P. receives research support from Seattle Genetics and Teva; serves on advisory boards for Cornerstone Pharmaceuticals and Teva; and serves on a speaker’s bureau for Gilead. S.M.A.’s institution receives support for research from Takeda Pharmaceutical Company and Seattle Genetics. A.Y. receives honoraria for consulting from Merck, Bristol-Myers Squibb, Bayer, Celgene, Incyte, Sanofi, Janssen R&D, Seattle Genetics, and Takeda Millennium; and research funding from Novartis, Johnson and Johnson, Curis, Roche, and Bristol-Myers Squibb. M.F. serves in a consulting role or on an advisory board for Bristol-Myers Squibb and Merck; receives honoraria from Seattle Genetics and Takeda; and receives research funding from Bristol-Myers Squibb, Merck, Takeda, and Seattle Genetics.

Figures

Figure 1.
Figure 1.
FFS and OS for patients with advanced-stage classical Hodgkin lymphoma after primary treatment with ABVD + brentuximab vedotin (ABVD+Bv) or AVD + brentuximab vedotin (AVD+Bv).
See this image and copyright information in PMC

Comment in

References

    1. Merli F, Luminari S, Gobbi PG, et al. . Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol. 2016;34(11):1175-1181. - PubMed
    1. Carde P, Karrasch M, Fortpied C, et al. . Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, International Prognostic Score ≥ 3, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 Intergroup Trial. J Clin Oncol. 2016;34(17):2028-2036. - PubMed
    1. Radford J, Illidge T, Counsell N, et al. . Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372(17):1598-1607. - PubMed
    1. Connors JM. Risk assessment in the management of newly diagnosed classical Hodgkin lymphoma. Blood. 2015;125(11):1693-1702. - PubMed
    1. Press OW, Li H, Schöder H, et al. . US Intergroup Trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816. J Clin Oncol. 2016;34(17):2020-2027. - PMC - PubMed

Publication types

MeSH terms

Supplementary concepts